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aBsTRacT
 The pharmacokinetics of enrofloxacin (EFC) was investigated in ducks fed with a normal diet, and in 
force-fed ducks, after a single intravenous (i.v.) and oral (p.o.) administration at doses of 10 mg/kg. Serum 
concentrations of EFC and ciprofloxacin (as metabolite of EFC) were determined by the HPLC method. The 
elimination half-lives of EFC after i.v. administration and compartmental pharmacokinetic analysis were 4.62 
± 0.62h and 6.39 ± 2.78 h in healthy and force-fed ducks, respectively. The values of total body clearance 
were 0.24 ± 0.03 L/h/kg in healthy and 0.18 ± 0.02 L/h/kg in force-fed ducks. The values of the volume of 
distribution (Vss) were 1.32 ± 0.18 L/kg and 1.31 ± 0.21 L/kg, respectively. After oral administration, maximum 
serum concentrations were 1.95 ± 0.36 µg/mL reached at 3.67 ± 4.26 h, and 4.25 ± 1.21 µg/mL at 1.25 ± 0.88 h, 
respectively. The serum concentrations of ciprofloxacin were significantly lower in the force-fed ducks. Longer 
enrofloxacin residence in force-fed ducks can be expected if compared to normally fed animals. 
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Introduction
Enrofloxacin (EFC), a second generation, broad spectrum fluoroquinolone, developed 
for use in veterinary medicine, is active against many Gram-positive and Gram-negative 
microorganisms (Pasteurella multocida, Riemerella anatipestifer, E. coli, Salmonella 
spp., Pseudomonas aeruginosa, Klebsiella pneumoniae) and Mycoplasma spp. (BrOWN, 
1996; GARCIA-OVANDO et al., 1999; KNOLL et al., 1999). Its disposition and that of its 
main metabolite, ciprofloxacin (CFC), have been studied in many domestic and wild 
avian species: chickens (ANADÓN et al., 1995; BUGYEI et al., 1999; GARCIA-OVANDO 
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et al., 1999; KNOLL et al., 1999), turkeys (HARITOVA et al., 2004; DIMITROVA et al., 2007; 
RUSSO et al., 2012), pheasants and Japanese quail (LASHEV et al., 2015), emu (KUMAR et 
al., 2015), greater rheas (DE LUKAS et al., 2005), ostrich (DE LUKAS et al., 2013), but the 
data for ducks (INTORRE et al., 1997; TANSAKUL et al., 2005) and geese (JIANG and SHI, 
2013; SHI et al., 2014) are scarce. 
Raising ducks for fatty liver production may be accompanied by diseases with 
bacterial etiology. Their therapy often requires antibiotic use. Although force-feeding 
does not induce diet-related pathological changes or lead to reversible steatosis when 
it is carried out according to professional standards (BENARD et al., 2006), during this 
period many physiological parameters in the birds change, leading to increased body 
weight, triglyceridemia, and high AST and lipase blood levels (BOGIN et al., 1984). 
Additionally, force-fed ducks’ body weight increases extensively mostly by increased 
liver mass and body fat, which is a predisposition for changes in the drug behavior of 
highly lipophilic substances, such as enrofloxacin. Such changes can provoke alterations 
in its pharmacokinetics when treatment is necessary for disease. These ducks, after force 
feeding, may also be useful as an experimental model for investigation of animals with 
excess body mass. This is why the aim of the paper was to investigate the pharmacokinetics 
of enrofloxacin, and its metabolite ciprofloxacin in force-fed ducks compared to normally 
fed ducks.
Materials and methods
Drug. A solution of enrofloxacin (Baytril® 5%, Bayer Animal Health GmbH D-51368 
Leverkusen, Germany) was used. the original drug form was diluted with distilled water 
to a concentration of 2.5% and after that was used for oral treatment.
Animals. Twenty-four ducks, divided into two groups, were used in the study. In the 
first experiment eleven-week old ducks (6 males and 6 females) were included, at the 
time just before the beginning of force-feeding, weighing 2.91-3.94 kg, and in the second 
trial there were thirteen-week old ducks (6 males and 6 females), at the end of force-
feeding, weighing 4.05-5.45 kg. All of them were hybrids of male Muscovy and female 
Peking ducks, reared on a private farm. Food and water were provided ad libitum. the 
feed was removed 18 hours before the experiments. Care and handling of animals were 
in accordance with the provisions for welfare of Regulation (EC) № 882/2004 of the 
European Parliament and of the Council of 29 April 2004, adopted by the Government 
of the Republic of Bulgaria in Ordinance № 20 of 01.11.2012. The experiments were 
approved by the Committee on the Ethical Treatment of Animals at Trakia University.
Study design. The first experiment was performed with 12 ducks at the time before 
the beginning of force-feeding. The birds were randomly divided into two groups of 6 
(3 male and 3 female) each. The first group was treated intravenously (in the brachial 
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vein) and the second - orally (by administration into the crop) at a dose of 10 mg/kg 
enrofloxacin. In the second experiment, the 12 ducks at the end of fattening period were 
also divided into two groups of 6 (3 males and 3 females) birds each. They were treated 
as described above. Before treatment, serum levels related to liver function, AST, ALT, 
cholesterol, triglycerides and LDH, of all birds were tested. 
Sampling collection. Blood samples (each 0.8 mL) were obtained from the v. 
brachialis of each bird without anticoagulant. After intravenous treatment, only the 
contralateral vein was used. times for sampling after i.v. treatment were 0.083, 0.25, 0.5, 
1, 3, 6, 9, 12, 18 and 24 h, respectively, and after p.o. administration 0.25, 0.5, 1, 3, 6, 9, 
12, 18 and 24 h. All blood samples were centrifuged for 15 min at 1800 g and the serum 
was separated. The obtained serum samples were stored at -20 °C for no longer than 2 
weeks until analysis.
Analytical method. Serum concentrations of enrofloxacin and its metabolite 
ciprofloxacin were assayed by the HPLC method (harItOVa et al., 2012). The system 
consisted of a Hipersil Spherisorb ODS-2(C18)-250 × 4.6-mm 5 µm column, a Surveyor 
LC Pump Plus, a Surveyor fluorescence detector, and a Surveyor Autosampler Plus 
(Thermo Fisher Scientific Inc., USA). The mobile phase was prepared with acetonitrile 
and 0.05 M potassium dihydrogen phosphate (25:75, v/v), and the pH was adjusted to 
3.5 with phosphoric acid (85%). The flow rate was 0.6 mL/min. Excitation and emission 
wavelengths were set at 277 nm and 418 nm. Peak area integrations were measured by 
the ChromQuest Chromatography Data System (Thermo Fisher Scientific Inc., USA). 
The external standards were enrofloxacin (enrofoxacin hydrochloride, Biovet Pestera, 
Bulgaria) and ciprofloxacin (ciprofloxacin hydrochloride, Actavis, Bulgaria). Standard 
solutions were prepared in drug-free duck serum at concentrations of 50, 100, 250, 500, 750 
and 1000 ng/mL. Serum samples (100 µL) were diluted with 400 µL of 0.1M phosphate 
buffer with pH 7.4, and vortexed for 0.5 min. After adding 3 mL of dichloromethane, the 
samples were mixed again for 1 min and centrifuged for 6 min at 1000 g. the organic 
phase was collected and was evaporated in a vacuum evaporator at 40 °C. The residue 
was dissolved in 100 µL demineralized water, and aliquots of 20 µL were injected into 
the HPLC system. The limit of quantification was 50 ng/mL for ciprofloxacin and 10 ng/
mL for enrofloxacin. The standard curves were linear over the tested range between LOQ 
and 1000 ng/mL (r2 = 0.999) and enrofloxacin did not interfere with ciprofloxacin. The 
accuracy was between 82 and 102% for the range of concentrations used. Inter-assay and 
intra-assay precisions were 2.47 and 1.20, respectively. 
Pharmacokinetic analysis. The analysis was carried out using specialized software 
(Phoenix 6.2.1; Pharsight, Mountain View, CA, USA). Compartmental analysis was used 
for the data after i.v. administration of enrofloxacin. The best fit was determined according 
to Akaike’s Information Criterion. Non-compartmental analysis was used for the data 
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after i.v. and p.o. administration of the drug. the area under the serum-concentration-
time curve (AUC) was calculated by the trapezoids method between the times 0 and 
24 h. The following pharmacokinetic parameters were computed: AUC0→∞ − area under 
curve from time 0 to infinite; AUC0→24 − area under the serum concentration-time curve 
from time zero to last time (24 h); t1/2α− distribution half- life; t1/2β − elimination half-
life; ClВ − total body clearance; MRT0→∞ − mean residence time from time 0 to infinite; 
MRT0→24 − mean residence time zero to last time (24 h); Vc – volume of distribution in the 
central compartment; Vss − volume of distribution at steady state; Vd(area) − area volume 
of distribution; t1/2λ − terminal half-life (non-compartmental analysis); Cmax – maximum 
serum levels; Tmax – time of Cmax; F − bioavailability; MAT0∞ − mean absorption time from 
time 0 to infinite; MAT0→24 − mean absorption time from time zero to last time (24 h) 
(TOUTAIN and BOUSQUET-MELOU, 2004). PK-PD indices AUC0-24h/MIC and Cmax/MIC 
were calculated on the basis of MIC (0.01 µg/mL) and MBC (0.06 µg/mL) values for E. 
coli O78/h12 (harItOVa et al., 2011).
Statistical analysis. The results are expressed as mean values ± standard deviations 
(SD). Descriptive statistics were performed with Statistica for Windows (Statistica 6.0.1, 
USA). The Mann–Whitney U test was used and P<0.05 was considered to be significant.
Results
The values of the selected biochemical parameters of normally and force-fed ducks 
are shown in Table 1. Cholesterol, triglycerides and LDH were significantly increased 
after force feeding. 
Table 1. Values of some biochemical parameters of normal and force-fed ducks (mean ± SD).
Parameter Unit Before force-feeding after force-feeding reference values
Glucose mmol/L 10.62 ± 3.18 11.24 ± 0.85 10.9-16.61
Cholesterol mmol/L 4.74 ± 0.61 13.48 ± 2.84* 3.3-7.21
Triglycerides mmol/L 0.44 ± 0.10 2.04 ± 1.24* 0.583 ± 0.1233
aSt U/L 46.71 ± 15.95 73.73 ± 34.34 28.32
ALT U/L 25.71 ± 5.97 54.09 ± 38.57 33.42
LDH U/L 648 ± 206 1500 ± 783* 104-9781
*Statistically significant difference between data on ducks before force-feeding and ducks with steatosis at P< 
0.05; 1STOJKOVSKI, 2001; 2FAIRBROTHER et al., 1990; 3HERMIER et al., 2003.
The serum concentration-time profiles of enrofloxacin and its main metabolite 
ciprofloxacin after single i.v. and p.o. administration of 10 mg/kg enrofloxacin are shown 
in Fig. 1 and 2. The EFC curves after i.v. administration were best described by the two-
compartment model. Its elimination half-life was longer and the AUC values were higher 
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in force-fed birds. The values of body clearance were lower after feeding. The values of 
Vc were higher, but these of Vdarea and Vss did not differ between the two groups (Table 2). 
Fig. 1. Serum concentrations of enrofloxacin () and ciprofloxacin () after a single 
intravenous dose of 10 mg/kg enrofloxacin in intact (---) and force-fed (––) ducks (mean ± SD)
After p.o. treatment, the non-compartment model was used for analysis of the data. 
The maximum serum concentrations were statistically significantly higher and were 
reached earlier in the force-fed ducks (Table 2). In the same group, the mean absorption 
time was insignificantly shorter. The absolute oral bioavailability of EFC was not 
changed significantly, but the relative oral bioavailability (Frelative = 100.AUCfed/AUCnormal) 
was higher (121%). The serum concentrations of ciprofloxacin as a metabolite after 
both administrations of EFC remained above the detection limit for at least 24h (Fig. 
1 and 2). The ciprofloxacin/enrofloxacin ratios of AUC values were lower after both 
administrations in the force-fed birds (table 2).
PK-PD indices, based on the MIC value of enrofloxacin and ciprofloxacin of 0.01 µg/
mL, are presented in Table 3. Cmax/MIC values were almost two-folds higher in force-fed 
ducks. A similar tendency was observed for AUC0-24h/MIC. Both PK-PD indices were 
higher than the breakpoint value of 10 for Cmax/MIC and of 125 for AUC0-24h/MIC. The 
values of Cmax/MBC and AUC0-24h/MBC were higher than these breakpoints, where MBC 
was 0.06 µg/mL (Table 3). 
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Table 2. Pharmacokinetic parameters (Mean ± SD) of enrofloxacin and its metabolite 
ciprofloxacin in ducks after single i.v. and p.o. administration at a dose of 10 mg/kg bw
Parameter Unit Before force-feeding With steatosis
Two-compartmental analysis, i.v. administration
Enrofloxacin Ciprofloxacin Enrofloxacin Ciprofloxacin
AUC0→∞ µg. h/mL 41.76 ± 4.82 - 55.8 ± 6.68* -
t1/2α h 0.46 ± 0.35 - 0.43 ± 0.34 -
t1/2β h 4.62 ± 0.62 - 6.39 ± 2.78* -
CLВ L/h/kg 0.24 ± 0.03 - 0.18 ± 0.02* -
Vc L/kg 0.58 ± 0.13 - 0.90 ± 0.13* -
Vss L/kg 1.32 ± 0.18 - 1.31 ± 0.21 -
Vd(area) L/kg 1.60 ± 0.17 - 1.66 ± 0.74 -
Non-compartmental analysis, i.v. administration
AUC0→24h µg. h/mL 41.73 ± 4.72 14.62 ± 2.37 54.05 ± 4.85 11.92 ± 5.39
AUC0→∞ µg. h/mL 44.66 ± 4.61 na 58.96 ± 6.48 na
MRT0 →24h h 4.30 ± 0.51 na 5.68 ± 0.63 na
MRT0→∞ h 5.96 ± 0.82 14.06 ± 10.26 8.19 ± 1.99 22.01 ± 6.21
t1/2λ h 12.36 ± 9.32 15.58 ± 5.39
Cmax µg/mL 2.9 ± 0.58 0.92 ± 0.41
tmax h 0.42 ± 0.30 4.25 ± 2.59
AUCc/AUCe 0.35 0.22
Non-compartmental analysis, p.o. administration
t1/2λ h 7.35 ± 1.71 15.42 ± 2.74 7.46 ± 2.99 10.5 ± 3.46
Cmax µg/mL 1.95 ± 0.36 0.51 ± 0.12 4.25 ± 1.21* 0.67 ± 0.2
tmax h 3.67 ± 4.26 8.25 ± 5.81 1.25 ± 0.88 5.13 ± 4.35
AUC0 →24h µg.h/mL 21.75 ± 4.07 6.96 ± 0.87 26.24 ± 3.38 7.77 ± 1.47
AUC0→∞ µg. h/mL 25.42 ± 4.35 na 27.80 ± 4.21 9.33 ± 1.35
MRT0 →24h h 7.95 ± 0.74 na 5.43 ± 1.05 na
MRT0→∞ h 11.49 ± 1.94 22.52 ± 4.23 7.08 ± 2.24 14.96 ± 3.33
MAT0 →24h h 3.65 ± 0.71 1.0 ± 1.32
MAT0→∞ h 5.53 ± 1.46 2.46 ± 2.4
F % 52.28 ± 8.55 49.02 ± 8.99
AUCc/AUCe 0.32 0.30
*Statistically significant difference between ducks before force-feeding and ducks with steatosis at P<0.05; AUC0→∞ − area under curve from time 0 to infinite; AUC0→24 − area under the serum concentration-time curve from time zero to last time (24 h); t1/2α− distribution half-life; t1/2β (t1/2λ) − elimination (terminal) half-life; ClВ − total body clearance; MRT0→∞ − mean residence time from time 0 to infinite; MRT0→24 − mean residence time zero to last time (24 h); Vc – volume of distribution in the central compartment; Vss − volume of distribution at steady state; Vd(area) − volume of distribution; Cmax – maximum serum levels; Tmax – time of Cmax; F − bio-availability; MAT0→∞ − mean absorption time from time 0 to infinite; MAT0→24 − mean absorption time from time zero to last time (24 h); F − bioavailability; AUCc/AUCe - relation between area under serum concentrations of ciprofloxacin and enrofloxacin.; na – not applicable due to extrapolation > 20%.
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Fig. 2. Serum concentrations of enrofloxacin () and ciprofloxacin () following a single 
oral dose of 10 mg/kg enrofloxacin in intact (---) and force-fed (––) ducks (mean ± SD)
Table 3. Pharmacokinetic-pharmacodynamic indices of enrofloxacin and its metabolite 
ciprofloxacin in ducks after single i.v. and p.o. administration at a dose of 10 mg/kg








* 195 246 425 492
AUC0 →24h/MIC 2175 2871 2624 3401
Cmax/MBC
* 32.5 41 70.8 82
AUC0 →24h/MBC 362.5 478.5 437.3 566.8
*MIC = 0.01 µg/mL; MBC = 0.06 µg/mL
Discussion 
Although EFC is a well investigated drug and its pharmacokinetics have been the 
subject of many articles regarding different bird species, the published data for ducks and 
geese are scarce. In Muscovy ducks Cmax of 0.99 µg/mL were achieved at Tmax of 1.38 h 
and MRT was 6.01 h (INtOrre et al., 1997). the value of t1/2β in Mallard ducks was 6.47 
h and bioavailability of 80.35% was observed (TANSAKUL et al., 2005). these data were 
similar to the data for the Gallinaceus species and geese (JIANG and SHI, 2013). the data 
for normally fed ducks in the present investigation were also similar to these, excluding 
the lower bioavailability in our case.
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Steatosis as a result of force-feeding is the reason for significant changes to liver 
function, which may be followed by different absorption, distribution or elimination of 
substances, in accordance with their chemical structure and behavior in the organism. 
Up to now, data about the pharmacokinetics of drugs in force-fed ducks have not been 
known, nor has any attempt been made to explain the changes compared to normally fed 
birds. We assumed that in our case the alterations found in the pharmacokinetics of force-
fed ducks were due to the function of fatty liver. 
The rate of distribution of EFC in both groups was similar, although the drug showed 
a higher volume of distribution in the central compartment in the force-fed ducks than 
in intact birds. The significantly lower clearance in this group of animals may be a 
prerequisite for the slower elimination of the antibiotic. Reduced drug metabolism, which 
probably provokes higher blood levels of enrofloxacin, could be another explanation of 
the observed changes. The registered differences led to higher area under the curves after 
both routes of administration, and to higher oral relative bioavailability of ENR. Decreased 
conversion of the parent drug to its main metabolite resulted in half the ratio between 
the values of area under the curves of ciprofloxacin and enrofloxacin. The present data 
were similar to the reported retarded elimination of bromosulfophtaleine and indocyanine 
green in force-fed ducks (BENGONE-NDONG et al., 1996). Insignificantly higher values of 
Cmax and AUC were found for enrofloxacin after p.o. treatment in force-fed ducks, which 
may contribute to the better efficacy of the fluoroquinolones. 
The PK-PD integration in both groups of ducks revealed that the applied dose of 10 
mg/kg can ensure clinical efficacy for treatment of infections provoked by highly sensitive 
pathogens with MIC of 0.01 µg/mL and MBC of 0.06 µg/mL, as has been observed in 
chicken (HARITOVA et al., 2011; MEKALA et al., 2014). The PK-PD indices can be high 
enough to guarantee clinical success against pathogens with MIC values of 0.125 µg/mL. 
Higher doses will be necessary for less sensitive bacteria. In order to avoid resistance 
development, the best strategy requires MIC determination of the specific pathogens 
in ducks, and administration of enrofloxacin in cases when breakpoint values of Cmax/
MIC>10-12 and for AUC0-24h/MIC>125 are achieved. Additional determination of MBC 
values can be used for early detection of the risk for resistance selection, if the difference 
between MBC and MIC is higher than four (harItOVa et al., 2011). Apparently, high 
values of PK-PD indices in force-fed ducks do not require additional adjustment of 
dosage regimen if compared to the normally fed birds. However further studies could be 
necessary to evaluate the pharmacokinetic behavior of enrofloxacin and its metabolite 
ciprofloxacin in forced fed ducks after a multiple regimen dosage.
In conclusion, ducks with fat liver absorbed and distributed enrofloxacin better 
in the body and eliminated it more slowly than normally fed birds. A lower degree of 
metabolism to ciprofloxacin can be expected in animals with liver steatosis. The observed 
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differences were not always statistically significant, but alterations in liver function may 
cause prolonged residence of enrofloxacin in force-fed, compared to normally fed ducks. 
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sažeTaK
Farmakokinetika enrofloksacina (EFC) primijenjenog intravenski i oralno u dozi od 10 mg/kg istražena je 
u normalno i prisilno hranjenih pataka. Serumske koncentracije EFC i ciprofloksacina (kao metabolita EFC) bile 
su određene visokotlačnom tekućinskom kromatografijom. Poluvrijeme izlučivanja EFC nakon i.v. primjene i 
farmakokinetičke analize po odjeljcima iznosilo je 4,62 ± 0,62 h u zdravih, a 6,39 ± 2,78 h u prisilno hranjenih. 
Vrijednosti ukupnog klirensa lijeka iz organizma bile su 0,24 ± 0,03 L/h/kg u zdravih i 0,18 ± 0,02 L/h/kg u 
prisilno hranjenih (šopanih). Vrijednosti volumena raspodjele (Vss) bile su 1,32 ± 0,18 L/kg i1,31 ± 0,21 L/kg. 
Najveće serumske koncentracije nakon oralne primjene bile su dosegnute nakon 3,67 ± 4,26 h, a iznosile su 
1,95 ± 0,36 µg/mL, dok su nakon intravenske primjene bile dosegnute nakon 1,25 ± 0,88 h, a iznosile su 4,25 
± 1,21 µg/mL. Serumske koncentracije ciprofloksacina bile su značajno niže u prisilno hranjenih pataka. Duže 
zadržavanje enrofloksacina može se očekivati u prisilno hranjenih pataka u odnosu na one normalno hranjene.
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